In a recent financial analyst call for the 2026 fiscal year, ALI HEALTH's (00241) Chairman and CEO Shen Difan announced that the company will take unified command of the pharmaceutical business segments operating under the "B2C+O2O" model. This move aims to enhance coordination and build synergistic strength across operations.

Shen Difan stated, "A dedicated task force has been established within the group for the pharmaceutical businesses in the B2C and O2O flash-sale sectors, all under the unified command of ALI HEALTH. We will meet consumer health needs across different scenarios."

Following the implementation of this "unified command" strategy, ALI HEALTH will leverage its B2C and O2O flash-sale systems to gain insights into the detailed health demands across tens of thousands of grid areas nationwide. This will enable the provision of more precise and practical traceability and digitalization services for pharmaceutical companies. By integrating far-field e-commerce, the flash-sale ecosystem, innovative drugs, medical services, and the pharmaceutical supply chain, the company aims to form a comprehensive, multi-faceted "full-stack pharmaceutical" platform.

ALI HEALTH's 2026 fiscal year performance report shows that as of March 31, 2026, the company achieved revenue of RMB 34.255 billion, a year-on-year increase of 12%. Net profit reached RMB 1.936 billion, up 35.2% year-on-year, while adjusted net profit amounted to RMB 2.326 billion, marking a 19.3% increase. The company's pharmaceutical business demonstrated solid growth momentum. Its inaugural medical AI product, "Hydrogen Ion," has officially launched, solidifying ALI HEALTH's new strategic focus on "full-stack pharmaceuticals + medical AI." Looking ahead, the company plans to deepen its long-term value creation in the healthcare sector, continuing to serve users, medical professionals, and ecosystem partners.